{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:57:00Z","timestamp":1791910620575,"version":"4.3.4"},"reference-count":60,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Drugs that act on the central nervous system (CNS) and have sedative effects can lead to abuse in humans. New CNS-active drugs often require evaluation of their abuse potential in dedicated animal models before marketing approval. Daridorexant is a new dual orexin receptor antagonist (DORA) with sleep-promoting properties in animals and humans. It was approved in 2022 in the United States and Europe for the treatment of insomnia disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>Nonclinical evaluation of abuse potential of daridorexant using three specific rat models assessing reinforcement, interoception, and withdrawal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Reinforcing effects of daridorexant were assessed in an operant rat model of intravenous drug self-administration. Similarity of interoceptive effects to those of the commonly used sleep medication zolpidem was tested in an operant drug discrimination task. Withdrawal signs indicative of physical dependence were evaluated upon sudden termination of chronic daridorexant treatment. Rat experiments were conducted at a dose range resulting in daridorexant plasma concentrations equaling or exceeding those achieved at the clinically recommended dose of 50\u2009mg in humans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Daridorexant had no reinforcing effects, was dissimilar to zolpidem in the drug discrimination task, and did not induce any withdrawal-related signs upon treatment discontinuation that would be indicative of physical dependence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Daridorexant showed no signs of abuse or dependence potential in rats. Our data indicate that daridorexant, like other DORAs, has a low potential for abuse in humans.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811231215415","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T05:23:51Z","timestamp":1701926631000},"page":"1249-1260","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-6555","authenticated-orcid":false,"given":"Michel A","family":"Steiner","sequence":"first","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Toeroek-Schafroth","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"},{"name":"Current affiliation: Galapagos GmbH, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Giusepponi","sequence":"additional","affiliation":[{"name":"Aptuit Srl, An Evotec Company, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Dacome","sequence":"additional","affiliation":[{"name":"Aptuit Srl, An Evotec Company, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Tessari","sequence":"additional","affiliation":[{"name":"Aptuit Srl, An Evotec Company, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"bibr1-02698811231215415","unstructured":"Australian Public Assessment Report for Suvorexant (2015) https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-suvorexant-150411.pdf"},{"key":"bibr2-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2021.105053"},{"key":"bibr3-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90208-Y"},{"key":"bibr4-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.241422"},{"key":"bibr5-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz076"},{"key":"bibr6-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000077"},{"key":"bibr7-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2017.03.006"},{"key":"bibr8-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201402258"},{"key":"bibr9-02698811231215415","volume-title":"84th annual scientific meeting of the college on problems of drug dependence","author":"Caro Y","year":"2022"},{"key":"bibr10-02698811231215415","unstructured":"Citizens Petition Daridorexant (2023) https:\/\/www.idorsia.us\/documents\/us\/media-releases\/2023_citizens-petition-dora.pdf"},{"key":"bibr11-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1803-19.2020"},{"key":"bibr12-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.02.063"},{"key":"bibr13-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0150-x"},{"key":"bibr14-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25680"},{"key":"bibr15-02698811231215415","unstructured":"Department of Justice (2014) Federal Register Vol. 79, No. 30. https:\/\/www.govinfo.gov\/content\/pkg\/FR-2014-02-13\/pdf\/2014-03124.pdf (interim rule) and https:\/\/www.govinfo.gov\/content\/pkg\/FR-2014-08-28\/pdf\/2014-20515.pdf (final rule; 08\/28\/2014 \/ Vol. 79, No. 167)"},{"key":"bibr16-02698811231215415","unstructured":"Department of Justice (2020) Federal Register Vol. 85, No. 67. https:\/\/www.govinfo.gov\/content\/pkg\/FR-2020-04-07\/pdf\/2020-07089.pdf (interim rule) and https:\/\/www.govinfo.gov\/content\/pkg\/FR-2021-03-03\/pdf\/2021-04183.pdf (final rule; 03\/03\/2021 \/ Vol. 86, No. 40)"},{"key":"bibr17-02698811231215415","unstructured":"Department of Justice (2022) Federal Register Vol. 87, No. 67. https:\/\/www.govinfo.gov\/content\/pkg\/FR-2022-04-07\/pdf\/2022-07322.pdf"},{"key":"bibr18-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1159\/000514961"},{"key":"bibr19-02698811231215415","unstructured":"EMA Approval Daridorexant (2022) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/quviviq#assessment-history-section"},{"key":"bibr20-02698811231215415","unstructured":"EMA Scientific Guideline: Non-clinical investigation of the dependence potential of medicinal products (2006). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-non-clinical-investigation-dependence-potential-medicinal-products_en.pdf"},{"key":"bibr21-02698811231215415","unstructured":"FDA Approval Letter Suvorexant (2014) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/204569Orig1s000Approv.pdf"},{"key":"bibr22-02698811231215415","unstructured":"FDA Approval Letter Lemborexant (2019) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2019\/212028Orig1s000ltr.pdf"},{"key":"bibr23-02698811231215415","unstructured":"FDA Approval Letter Daridorexant (2022) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214985Orig1s000Approv.pdf"},{"key":"bibr24-02698811231215415","unstructured":"FDA Guidance for Industry Assessment of Abuse Potential of Drugs (2017) https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/assessment-abuse-potential-drugs"},{"key":"bibr25-02698811231215415","unstructured":"FDA Integrated Review on Daridorexant (2022) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214985Orig1s000IntegratedR.pdf"},{"key":"bibr26-02698811231215415","unstructured":"FDA Prescribing Information for Ativan (lorazepam). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/017794s044lbl.pdf"},{"key":"bibr27-02698811231215415","unstructured":"FEARS (FDA Adverse Events Reporting System) database. https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/7a47a261-d58b-4203-a8aa-6d3021737452\/state\/analysis"},{"key":"bibr28-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2011.03.001"},{"key":"bibr29-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199303000-00017"},{"key":"bibr30-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050422"},{"key":"bibr31-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1038\/nature04071"},{"key":"bibr32-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn8238"},{"key":"bibr33-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1007\/s00429-021-02449-8"},{"key":"bibr34-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.15593"},{"key":"bibr35-02698811231215415","first-page":"399","volume":"148","author":"Koechlin BA","year":"1965","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr36-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00980-8"},{"key":"bibr37-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001561"},{"key":"bibr38-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2008.01.001"},{"key":"bibr39-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54826-3"},{"key":"bibr40-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00436-1"},{"key":"bibr41-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2004.05.084"},{"key":"bibr42-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1046"},{"key":"bibr43-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001182"},{"key":"bibr44-02698811231215415","unstructured":"NSDUH, National Survey on Drug Use and Health. https:\/\/nsduhweb.rti.org\/respweb\/homepage.cfm"},{"key":"bibr45-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05954-0"},{"key":"bibr46-02698811231215415","first-page":"100","volume":"226","author":"Ryan GP","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr47-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2092"},{"key":"bibr48-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1007\/BF00174367"},{"key":"bibr49-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2016.06.010"},{"key":"bibr50-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0054-4"},{"key":"bibr51-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000516"},{"key":"bibr52-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.167"},{"key":"bibr53-02698811231215415","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00691"},{"key":"bibr54-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145712000193"},{"key":"bibr55-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.224"},{"key":"bibr56-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(89)90187-2"},{"key":"bibr57-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.241596"},{"key":"bibr58-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab224"},{"key":"bibr59-02698811231215415","doi-asserted-by":"publisher","DOI":"10.3109\/01677063.2011.566953"},{"key":"bibr60-02698811231215415","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0650-4"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811231215415","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811231215415","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811231215415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:11:33Z","timestamp":1777507893000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811231215415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1177\/02698811231215415"],"URL":"https:\/\/doi.org\/10.1177\/02698811231215415","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}